Figure 2.

Loss of hepatitis B virus (HBV) surface antigen (HBsAg) in (A) HBV e-antigen (HBeAg)-seropositive patients and (B) HBeAg-seronegative patients, with sustained undectable HBV DNA levels in separate trials with extended tenofovir disoproxil fumarate (TDF) or entecavir treatment, or 1 year of peginterferon treatment. Trials are not head-to-head comparisons and were conducted in different patient populations using different trial designs. NA indicates not applicable. Adapted from Marcellin et al, Gish et al, Marcellin et al, Buster et al, Heathcote et al, Marcellin et al, Heathcote et al, Janssen et al, Marcellin et al, Shouval et al, Chang et al, Brunetto et al, Lai et al.^{5,12,14–19,21–23,34,35}